Context Therapeutics Inc (NASDAQ: CNTX) on Tuesday, plunged -4.88% from the previous trading day, before settling in for the closing price of $1.23. Within the past 52 weeks, CNTX’s price has moved between $0.49 and $2.40.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 4.72%. The company achieved an average annual earnings per share of 30.98%. With a float of $58.82 million, this company’s outstanding shares have now reached $89.70 million.
Context Therapeutics Inc (CNTX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Context Therapeutics Inc is 34.43%, while institutional ownership is 43.42%. The most recent insider transaction that took place on Jun 09 ’25, was worth 70,080. In this transaction Chief Executive Officer of this company bought 100,000 shares at a rate of $0.70, taking the stock ownership to the 920,190 shares. Before that another transaction happened on Jun 06 ’25, when Company’s Chief Legal Officer, Corp. Sec bought 20,000 for $0.58, making the entire transaction worth $11,520. This insider now owns 29,000 shares in total.
Context Therapeutics Inc (CNTX) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.22 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.09) by -0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.01% during the next five years compared to 4.72% growth over the previous five years of trading.
Context Therapeutics Inc (NASDAQ: CNTX) Trading Performance Indicators
Context Therapeutics Inc (CNTX) is currently performing well based on its current performance indicators. A quick ratio of 19.04 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.40, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.39 in one year’s time.
Technical Analysis of Context Therapeutics Inc (CNTX)
The latest stats from [Context Therapeutics Inc, CNTX] show that its last 5-days average volume of 0.4 million was superior to 0.23 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 12.61%.
During the past 100 days, Context Therapeutics Inc’s (CNTX) raw stochastic average was set at 62.00%, which indicates a significant increase from 2.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1479 in the past 14 days, which was higher than the 0.0765 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0301, while its 200-day Moving Average is $0.8333. Now, the first resistance to watch is $1.2307. This is followed by the second major resistance level at $1.2913. The third major resistance level sits at $1.3267. If the price goes on to break the first support level at $1.1347, it is likely to go to the next support level at $1.0993. Assuming the price breaks the second support level, the third support level stands at $1.0387.
Context Therapeutics Inc (NASDAQ: CNTX) Key Stats
Market capitalization of the company is 104.95 million based on 89,704K outstanding shares. Right now, sales total 0 K and income totals -26,730 K. The company made 0 K in profit during its latest quarter, and -8,830 K in sales during its previous quarter.
